Bio­phar­ma in­dus­try's vac­cine pipeline lacks ‘depth,' with an overem­pha­sis on Covid — re­port

There are too many Covid vac­cines in de­vel­op­ment, and many oth­er in­fec­tious dis­eases where lit­tle work is get­ting done by biotech and phar­ma com­pa­nies. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.